Abstract 16390: Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients

Danny M Claassens,Gerrit J.A. Vos,Cornelis Boersma,Thomas O. Bergmeijer,Rik Hermanides,Arnoud van t Hof,Pim van der Harst,Emanuele Barbato,Carmine Morisco,Richard M. Tjon Joe Gin,Folkert W. Asselbergs,Arend Mosterd,Jean-Paul R. Herrman,Willem Dewilde,Maarten J. Postma,Vera H.M. Deneer,Jurriën M. ten Berg

Abstract 16390: Cost-effectiveness of a CYP2C19 Genotype-guided Antiplatelet Strategy in ST-elevation Myocardial Infarction Patients

2020

Danny M Claassens
Gerrit J.A. Vos
Cornelis Boersma
Thomas O. Bergmeijer
Rik Hermanides
Arnoud van t Hof
Pim van der Harst
Emanuele Barbato
Carmine Morisco
Richard M. Tjon Joe Gin
Folkert W. Asselbergs
Arend Mosterd
Jean-Paul R. Herrman
Willem Dewilde
Maarten J. Postma
Vera H.M. Deneer
Jurriën M. ten Berg

Introduction: The POPular Genetics trial demonstrated that a genotype-guided strategy to select antiplatelet therapy in patients with ST-elevation myocardial infarction (STEMI) compared to universa...

Keywords:

Myocardial infarction
cyp2c19 genotype
Medicine
Internal medicine
cost effectiveness
in patient
Cardiology
st elevation myocardial infarction

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations